Kingsview Wealth Management LLC Purchases Shares of 45,093 Bristol Myers Squibb Company $BMY

Kingsview Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,093 shares of the biopharmaceutical company’s stock, valued at approximately $2,598,000.

Other institutional investors also recently modified their holdings of the company. Beacon Pointe Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $13,408,000. Kimelman & Baird LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $895,000. 49 Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $210,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in Bristol Myers Squibb in the 2nd quarter valued at $906,000. Finally, Twin Lakes Capital Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at $275,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BMY shares. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Guggenheim reaffirmed a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating on the stock. Roth Capital started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $66.62 on Friday. The firm has a market cap of $136.09 billion, a price-to-earnings ratio of 14.67, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a 50-day moving average price of $61.76 and a 200 day moving average price of $59.68.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the firm earned $1.46 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.